Lithium Supplementation Shows Promise in Preventing and Reversing Alzheimer's in Mice

A new study published in Nature suggests that replenishing lithium in the brain may prevent, and potentially reverse, Alzheimer's disease. By examining human brain tissue and conducting mouse experiments, researchers found that declining lithium levels in the brain are closely linked to memory loss and hallmark Alzheimer's pathologies, including β-amyloid plaques and tau protein tangles.

The experiments showed that certain lithium compounds—such as lithium orotate—could reverse brain damage and restore memory in mice, whereas the commonly used lithium carbonate showed no such benefit. Neuroscientists called the findings groundbreaking, noting that existing Alzheimer's drugs typically target a single pathological mechanism, while lithium may act on multiple fronts.

Globally, more than 55 million people live with dementia, most with Alzheimer's disease. Current treatments can only slow cognitive decline, not halt or reverse it. Lithium has long been used as a mood stabilizer, becoming a standard therapy for bipolar disorder in the 1970s. Epidemiological data have also linked trace lithium in drinking water to lower dementia rates, though past clinical trials have been inconclusive.

In this study, Harvard Medical School researchers confirmed for the first time that lithium naturally exists in the brain and uncovered its role in Alzheimer's: β-amyloid plaques “trap” lithium, reducing its availability; this deficiency, in turn, promotes further plaque formation, creating a vicious cycle. Lithium orotate, less prone to plaque binding, demonstrated strong therapeutic effects in animal models.

While the mouse results require further validation, researchers remain cautiously optimistic. Future work will aim to clarify how lithium depletion begins and to advance clinical trials. If proven effective, lithium could emerge as a breakthrough therapy for Alzheimer's disease.